JP7368642B2 - 妊婦の子宮頸部剥離細胞から胎盤栄養膜細胞を分離する方法 - Google Patents
妊婦の子宮頸部剥離細胞から胎盤栄養膜細胞を分離する方法 Download PDFInfo
- Publication number
- JP7368642B2 JP7368642B2 JP2022573784A JP2022573784A JP7368642B2 JP 7368642 B2 JP7368642 B2 JP 7368642B2 JP 2022573784 A JP2022573784 A JP 2022573784A JP 2022573784 A JP2022573784 A JP 2022573784A JP 7368642 B2 JP7368642 B2 JP 7368642B2
- Authority
- JP
- Japan
- Prior art keywords
- hla
- cells
- cell
- sorting
- channel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004027 cell Anatomy 0.000 title claims description 108
- 210000002993 trophoblast Anatomy 0.000 title claims description 36
- 230000003169 placental effect Effects 0.000 title claims description 7
- 238000000034 method Methods 0.000 claims description 86
- 238000001514 detection method Methods 0.000 claims description 44
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 31
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 31
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 239000000872 buffer Substances 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 14
- 239000006285 cell suspension Substances 0.000 claims description 13
- 206010011878 Deafness Diseases 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 238000010276 construction Methods 0.000 claims description 8
- 208000016354 hearing loss disease Diseases 0.000 claims description 8
- 102100029761 Cadherin-5 Human genes 0.000 claims description 7
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 claims description 7
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 7
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 7
- 230000002759 chromosomal effect Effects 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 6
- 239000013504 Triton X-100 Substances 0.000 claims description 5
- 229920004890 Triton X-100 Polymers 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 238000002372 labelling Methods 0.000 claims description 5
- 208000002903 Thalassemia Diseases 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000012864 cross contamination Methods 0.000 claims description 3
- 231100000895 deafness Toxicity 0.000 claims description 3
- 210000003917 human chromosome Anatomy 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 43
- 108020004414 DNA Proteins 0.000 description 19
- 239000011324 bead Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 210000000349 chromosome Anatomy 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 231100000888 hearing loss Toxicity 0.000 description 5
- 230000010370 hearing loss Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000002669 amniocentesis Methods 0.000 description 4
- 210000004381 amniotic fluid Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000003761 preservation solution Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 206010000234 Abortion spontaneous Diseases 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000015994 miscarriage Diseases 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102100029375 Crk-like protein Human genes 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101000919315 Homo sapiens Crk-like protein Proteins 0.000 description 2
- 101000713590 Homo sapiens T-box transcription factor TBX1 Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100036771 T-box transcription factor TBX1 Human genes 0.000 description 2
- 210000002593 Y chromosome Anatomy 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 201000006288 alpha thalassemia Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004252 chorionic villi Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000003793 prenatal diagnosis Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100034665 Clathrin heavy chain 2 Human genes 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101150034593 Gjb2 gene Proteins 0.000 description 1
- 208000032041 Hearing impaired Diseases 0.000 description 1
- 102100038145 Homeobox protein goosecoid-2 Human genes 0.000 description 1
- 101000899442 Homo sapiens Cadherin-23 Proteins 0.000 description 1
- 101000946482 Homo sapiens Clathrin heavy chain 2 Proteins 0.000 description 1
- 101001032616 Homo sapiens Homeobox protein goosecoid-2 Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001070786 Homo sapiens Platelet glycoprotein Ib beta chain Proteins 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 241000665848 Isca Species 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 102100034168 Platelet glycoprotein Ib beta chain Human genes 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091006703 SLC25A1 Proteins 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 102100036216 Tricarboxylate transport protein, mitochondrial Human genes 0.000 description 1
- 208000006038 Urogenital Abnormalities Diseases 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009598 prenatal testing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 102200145334 rs2274084 Human genes 0.000 description 1
- 102200145330 rs72474224 Human genes 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Dispersion Chemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110549947.8 | 2021-05-20 | ||
| CN202110549947.8A CN112980779B (zh) | 2021-05-20 | 2021-05-20 | 一种从孕妇宫颈脱落细胞中分离胎盘滋养层细胞的方法 |
| PCT/CN2022/081234 WO2022242285A1 (zh) | 2021-05-20 | 2022-03-16 | 一种从孕妇宫颈脱落细胞中分离胎盘滋养层细胞的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527246A JP2023527246A (ja) | 2023-06-27 |
| JP7368642B2 true JP7368642B2 (ja) | 2023-10-24 |
Family
ID=76337075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573784A Active JP7368642B2 (ja) | 2021-05-20 | 2022-03-16 | 妊婦の子宮頸部剥離細胞から胎盤栄養膜細胞を分離する方法 |
Country Status (8)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112980779B (zh) | 2021-05-20 | 2021-08-24 | 广州凯普医药科技有限公司 | 一种从孕妇宫颈脱落细胞中分离胎盘滋养层细胞的方法 |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002040018A (ja) | 2000-05-12 | 2002-02-06 | F Hoffmann La Roche Ag | 母体から栄養芽層細胞を単離する方法 |
| JP2005500861A (ja) | 2001-09-06 | 2005-01-13 | モナシュ ユニバーシティ | 細胞を単離する方法及びその使用 |
| WO2005047532A1 (en) | 2003-11-17 | 2005-05-26 | Gribbles Molecular Science Pty Ltd | Improved method of performing genetic analyses on reproductive tract cell samples |
| JP2006523100A (ja) | 2003-04-03 | 2006-10-12 | モナリザ メディカル， リミテッド | 経子宮頸細胞を使用する非侵襲的出生前遺伝子診断 |
| JP2009531033A (ja) | 2006-03-23 | 2009-09-03 | バイオセプト インコーポレイティッド | 胎児栄養膜の単離 |
| JP2010525382A (ja) | 2007-04-19 | 2010-07-22 | エルディティ レーザー ディスプレイ テクノロジー ゲーエムベーハー | 映写面に画像を映写する画像映写方法および画像映写装置 |
| US20120036587A1 (en) | 2009-04-14 | 2012-02-09 | Institut Gustave Roussy | Prostate cancer cell lines and their use in screening method |
| US20120149014A1 (en) | 2009-04-21 | 2012-06-14 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
| WO2014201138A1 (en) | 2013-06-11 | 2014-12-18 | Stelling James R | Method for detection of fetal abnormalities |
| JP2015533504A (ja) | 2012-10-19 | 2015-11-26 | ウェイン ステイト ユニヴァーシティ | 出生前診断のための頚管粘液における胎性栄養膜細胞の同定および分析 |
| JP2015524054A5 (US20030157376A1-20030821-M00001.png) | 2013-05-23 | 2016-07-07 | ||
| CN107312747A (zh) | 2016-12-20 | 2017-11-03 | 华东医药（杭州）基因科技有限公司 | 一种免疫磁珠法分离胎盘滋养层细胞的方法 |
| JP2019516398A (ja) | 2016-04-06 | 2019-06-20 | ウェイン ステート ユニバーシティＷａｙｎｅ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ | 子宮頸管より採取された絨毛外栄養膜細胞からの胎児ｄｎａの単離と分析 |
| WO2019153032A1 (en) | 2018-02-07 | 2019-08-15 | University Of South Australia | Pre-natal cell isolation |
| US20200102533A1 (en) | 2018-10-02 | 2020-04-02 | Hung-Wei Wu | Cell sorting method and system |
| WO2020245459A1 (en) | 2019-06-07 | 2020-12-10 | Arcedi Biotech Aps | Isolation of fetal cells using facs |
| WO2021009682A1 (en) | 2019-07-15 | 2021-01-21 | Menarini Biomarkers Singapore Pte Ltd | Compositions and methods for isolating, detecting, and analyzing fetal cells |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE161960T1 (de) * | 1988-12-06 | 1998-01-15 | Flinders Technologies Pty Ltd | Isolierung von fetalen zellen aus mütterlichem blut zur ausführung von pränataler diagnostik |
| BR9306867A (pt) * | 1992-07-17 | 1998-12-08 | Aprogenex Inc | Enriquecimento e identificação de células fetais do sangue materno para a hibridização in situ |
| US5714325A (en) * | 1993-09-24 | 1998-02-03 | New England Medical Center Hospitals | Prenatal diagnosis by isolation of fetal granulocytes from maternal blood |
| JPH11503320A (ja) * | 1995-04-07 | 1999-03-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｈｌａ−ｇ検出用抗体 |
| US20050181429A1 (en) * | 2003-04-03 | 2005-08-18 | Monaliza Medical Ltd. | Non-invasive prenatal genetic diagnosis using transcervical cells |
| ITTO20070307A1 (it) * | 2007-05-04 | 2008-11-05 | Silicon Biosystems Spa | Metodo e dispositivo per la diagnosi prenatale non-invasiva |
| CN101726585A (zh) * | 2009-11-30 | 2010-06-09 | 宁波普赛微流科技有限公司 | 一种基于微流控芯片的流式细胞仪 |
| WO2013174948A1 (en) * | 2012-05-24 | 2013-11-28 | Rarecells | Process for multi-analyses of rare cells extracted or isolated from biological samples through filtration |
| CN103983794B (zh) * | 2013-02-12 | 2016-06-15 | 李木 | 一种微流控芯片及一种微流控方法 |
| CN108265051B (zh) * | 2016-12-30 | 2020-08-25 | 张婧 | 用于从母体捕获和分离胎儿细胞的无创方法和试剂盒 |
| CN108535228B (zh) * | 2018-04-03 | 2020-12-25 | 德运康明(厦门)生物科技有限公司 | 一种从孕妇外周血中分离游离胎儿细胞的方法 |
| CN110117571B (zh) * | 2019-05-08 | 2023-01-31 | 南方医科大学南方医院 | 无创获取胎儿稀有细胞的试剂盒及其方法 |
| CN111304153A (zh) * | 2019-12-17 | 2020-06-19 | 广东凯普生物科技股份有限公司 | 一种分离滋养层细胞的方法 |
| CN111440696B (zh) * | 2020-02-26 | 2023-02-24 | 德运康明(厦门)生物科技有限公司 | 胎儿细胞捕获模块、用于胎儿细胞捕获的微流控芯片，及它们的使用方法 |
| CN112980779B (zh) | 2021-05-20 | 2021-08-24 | 广州凯普医药科技有限公司 | 一种从孕妇宫颈脱落细胞中分离胎盘滋养层细胞的方法 |
-
2021
- 2021-05-20 CN CN202110549947.8A patent/CN112980779B/zh active Active
-
2022
- 2022-03-16 JP JP2022573784A patent/JP7368642B2/ja active Active
- 2022-03-16 AU AU2022277079A patent/AU2022277079B2/en active Active
- 2022-03-16 BR BR112022024743-5A patent/BR112022024743B1/pt active IP Right Grant
- 2022-03-16 EP EP22803614.1A patent/EP4144834B1/en active Active
- 2022-03-16 US US18/009,740 patent/US11796443B2/en active Active
- 2022-03-16 KR KR1020227043777A patent/KR102626620B1/ko active IP Right Grant
- 2022-03-16 WO PCT/CN2022/081234 patent/WO2022242285A1/zh unknown
Patent Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002040018A (ja) | 2000-05-12 | 2002-02-06 | F Hoffmann La Roche Ag | 母体から栄養芽層細胞を単離する方法 |
| JP2005500861A (ja) | 2001-09-06 | 2005-01-13 | モナシュ ユニバーシティ | 細胞を単離する方法及びその使用 |
| JP2006523100A (ja) | 2003-04-03 | 2006-10-12 | モナリザ メディカル， リミテッド | 経子宮頸細胞を使用する非侵襲的出生前遺伝子診断 |
| WO2005047532A1 (en) | 2003-11-17 | 2005-05-26 | Gribbles Molecular Science Pty Ltd | Improved method of performing genetic analyses on reproductive tract cell samples |
| JP2009531033A (ja) | 2006-03-23 | 2009-09-03 | バイオセプト インコーポレイティッド | 胎児栄養膜の単離 |
| JP2010525382A (ja) | 2007-04-19 | 2010-07-22 | エルディティ レーザー ディスプレイ テクノロジー ゲーエムベーハー | 映写面に画像を映写する画像映写方法および画像映写装置 |
| US20120036587A1 (en) | 2009-04-14 | 2012-02-09 | Institut Gustave Roussy | Prostate cancer cell lines and their use in screening method |
| US20120149014A1 (en) | 2009-04-21 | 2012-06-14 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
| JP2015533504A (ja) | 2012-10-19 | 2015-11-26 | ウェイン ステイト ユニヴァーシティ | 出生前診断のための頚管粘液における胎性栄養膜細胞の同定および分析 |
| JP2015524054A5 (US20030157376A1-20030821-M00001.png) | 2013-05-23 | 2016-07-07 | ||
| WO2014201138A1 (en) | 2013-06-11 | 2014-12-18 | Stelling James R | Method for detection of fetal abnormalities |
| US20160090631A1 (en) | 2013-06-11 | 2016-03-31 | James R. STELLING | Method for detection of fetal abnormalities |
| JP2019516398A (ja) | 2016-04-06 | 2019-06-20 | ウェイン ステート ユニバーシティＷａｙｎｅ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ | 子宮頸管より採取された絨毛外栄養膜細胞からの胎児ｄｎａの単離と分析 |
| CN107312747A (zh) | 2016-12-20 | 2017-11-03 | 华东医药（杭州）基因科技有限公司 | 一种免疫磁珠法分离胎盘滋养层细胞的方法 |
| WO2019153032A1 (en) | 2018-02-07 | 2019-08-15 | University Of South Australia | Pre-natal cell isolation |
| US20200102533A1 (en) | 2018-10-02 | 2020-04-02 | Hung-Wei Wu | Cell sorting method and system |
| WO2020245459A1 (en) | 2019-06-07 | 2020-12-10 | Arcedi Biotech Aps | Isolation of fetal cells using facs |
| WO2021009682A1 (en) | 2019-07-15 | 2021-01-21 | Menarini Biomarkers Singapore Pte Ltd | Compositions and methods for isolating, detecting, and analyzing fetal cells |
Non-Patent Citations (1)
| Title |
|---|
| 福田 敏男、新井 史人 監修，細胞分離・操作技術の最前線＜＜普及版＞＞，2015年04月07日，p. 130-133 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022024743B1 (pt) | 2024-03-05 |
| US11796443B2 (en) | 2023-10-24 |
| WO2022242285A1 (zh) | 2022-11-24 |
| EP4144834B1 (en) | 2024-10-23 |
| US20230228667A1 (en) | 2023-07-20 |
| KR102626620B1 (ko) | 2024-01-17 |
| JP2023527246A (ja) | 2023-06-27 |
| KR20230004915A (ko) | 2023-01-06 |
| CN112980779A (zh) | 2021-06-18 |
| CN112980779B (zh) | 2021-08-24 |
| AU2022277079A1 (en) | 2023-01-19 |
| AU2022277079B2 (en) | 2024-07-04 |
| EP4144834A1 (en) | 2023-03-08 |
| BR112022024743A2 (US20030157376A1-20030821-M00001.png) | 2023-06-27 |
| EP4144834A4 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hahn* et al. | Current applications of single-cell PCR | |
| Vona et al. | Enrichment, immunomorphological, and genetic characterization of fetal cells circulating in maternal blood | |
| KR101781147B1 (ko) | 대립유전자, 게놈 및 전사체 검출을 위한 방법 및 유전자형 분석 패널 | |
| US7368234B2 (en) | Physical mapping method using molecular combing technique allowing positioning of a great number of clones within a genome | |
| CN104745718B (zh) | 一种检测人类胚胎染色体微缺失和微重复的方法 | |
| WO2017024690A1 (zh) | 一种单管高通量测序文库的构建方法 | |
| US20230092810A1 (en) | Fetal cell capture module and microfluidic chip for fetal cell capture and methods for using the same | |
| JP2004528027A (ja) | 診断検査 | |
| EP1891204B1 (en) | Method of fetal cell enrichment | |
| CN107267628A (zh) | 胚胎植入前染色体异常检测试剂盒 | |
| JP7368642B2 (ja) | 妊婦の子宮頸部剥離細胞から胎盤栄養膜細胞を分離する方法 | |
| CN109371121A (zh) | 一种用于产前诊断染色体异常的试剂盒 | |
| WO2005047532A1 (en) | Improved method of performing genetic analyses on reproductive tract cell samples | |
| CN105861657B (zh) | 一种与奶牛乳房炎抗性相关的cnv片段及其应用 | |
| CN111781360A (zh) | 游离细胞捕获探针及其相关产品和用途 | |
| WO2013163935A1 (zh) | 一种纯净的胎儿完整基因组dna的分离获取方法 | |
| RU2808260C1 (ru) | Способ отделения клеток плацентарного трофобласта от отслоившихся клеток шейки матки беременных женщин | |
| CN107312779B (zh) | 用于分离滋养层细胞的核酸适配体、分离滋养层细胞的方法和染色体拷贝数变异分析的方法 | |
| CN114457143A (zh) | 一种构建cnv检测文库的方法及cnv检测方法 | |
| Bianchi | Progress in the genetic analysis of fetal cells circulating in maternal blood | |
| CN115807103B (zh) | 36个红细胞血型系统基因全编码区序列同步检测基因分型方法、探针集及试剂盒 | |
| CN111235104A (zh) | 一种孕妇外周血胎儿有核红细胞分离纯化方法及分离仪 | |
| CN110117571A (zh) | 无创获取胎儿稀有细胞的试剂盒及其方法 | |
| CN116445478B (zh) | 一种构建ighv基因文库的引物组合及其应用 | |
| CN115109780B (zh) | 一种特异性识别并结合循环胎儿有核红细胞的核酸适体、互补序列及它们的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221129 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221129 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20221129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230613 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230905 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230906 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231010 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231012 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7368642 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |